Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are you that hungry? Give the Dr. a chance
Chris Otiko 4 WEEKS,AS WE KNOW,COULD BE 4 MONTHS.TOO.ALWAYS A DIFFERENT EXCUSE.IT WILL BE A MIRACLE IF HE EVER DELIVERS ON TIME.JUST LIKE THE BS $600K CONTRACT.LOL.
Wednesday makes 3 weeks since this was stated in the last PR:
President and CEO, Dr. Chris Otiko said, “Since both of these products are a new and improved formulation, we decided now would be the best time to conduct additional testing before we begin large scale distribution. The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after”.
looks down to me. :(
I see good things about to happen GO VDRM
Mr. slops - what we thinking???
So is that your bid of 3,000,000.??
I DO BELIEVE THUS I AM THE ONLY BUYER.LOL.YOU GUYS DO NOT BELIEVE,THUS WE ARE AT .006S.LOL.
It’s a process mate!!!! Like everything else in life LOL. This is not a short cut get rich stock. Give it time, don’t go ahead of yourself like that. If the Massive orders on the way is not enough for you and FDA registered as well, I don’t know what exactly you’re looking for at this moment. With such mentioned above, this company is UNDERVALUED: If you don’t believe me, go and check ENZC LMAO
<<<<0.02 is a kid’s game>>>>That can NOT Happen,when you have only one Bidder supporting the bids,from keeping her from Crashing lower.We can not talk big games,when we do Nothing to support the small games.lol.
IMO - once it runs we’ll never see these low PPS again. Company already has the re occurring revenue. Big deal and buyout potential. The Dr. has built something special here!
Expecting much higher than that !
We’re pretty close to that already. With the catalyst already in the making, 0.02 is a kid’s game
I BELIEVE WE WILL SEE .02S THIS YEAR IMO.
Yup, there is not stopping this. Holding long now, millionaire in the making. The orders will flow from the sky like rain
A BIG RUN TO .02S IS COMING IMO.LET US REMEMBER THE .005S AND THE .006S:)
I totally agree, the PR said "Within 4 Weeks", so it could be less... Mid July could be perfect... Crossing fingers for such explosions'
Sounds about right, mid July it is.
Yup, been holding shares for a long time.
I think the four week possible conclusion to testing and shipping could start around July 15th. Been long time a coming.!!
Hopefully, $VDRM run will begin by end of July.
End year? Naah 1 month tops this should leave people speechless!!! Supernova
Plenty will happen by Year End GO VDRM
Agree, but I am in no hurry!
Still accumulating
How would you feel with SMALL ORDERS?
Completely agree. I think I am “large”, my girlfriend disagrees
The problem is that "large" is a relative term.
Large in what context?
Large relative to past orders? Doesn't help much as past orders were so tiny that even a "large" order could still be pretty small.
Large relative to production capacity? Might be scary, as I still think Otiko has been brewing this stuff up in his bath tub. How does VDRM gear up to fulfill such a "large" order?
Large enough to signal really substantial revenues and prospective reorders to provide a continuous income stream? While I still would have a question about how production could be ramped up, we can hope.
VDRM Not just another penny stock anything could happen here
I believe you might have missed a 2 in front of that 5….
$.25
ALL BS as usual IMVVHO...LMFAO.
As mentioned and shown several times with links...
The formula is the EXACT same as the one the Brewer Company sells on their website. They OBVIOUSLY did/already did testing...
More dangling of the carrot as usual/vagueness etc.
LMFAO.
one of these big names,and it goes to .05 imo,.
I’m also left wondering if the large Purchase Orders might be for a leading drug store chain like a CVS or Walgreens or etc, etc????
I’m wondering How LARGE are these Purchase Orders he is referencing???
The first sentence below from the latest PR says it all for me to keep accumulating:
Dr. Otiko continued, “The products have tested well so far, and we expect they will continue to do so without issue, but because they are both different formulations than the original, and since we are moving much closer to having to fulfill large purchase orders, we felt we should implement these precautionary measures at this time in an abundance of caution. The last thing we want is to have a problem down the road when a correction would be much harder to address. Taking this step now will minimize the potential for such problems later.”
Ohh bush, you are counting the days left!!! Good mate... About the sellers, these are day traders, they do not care about if this will go ballistic in 3 weeks or not. Honestly, there is a great chance they do not even know about the news... They only see the technical in the charts... Nothing else, bread and butter of the day, live and run today, to die another day...
3 WEEKS LEFT BEFORE THE PRODUCT RESULTS.THIS THING WILL GO BALLISTIC SOMETIME THIS YEAR.SELLERS KEEP ON SELLING:)))
Our days are coming.
huge volume today. sigh.
And here we are one weekend closer. Been waiting a long time for this to get a sustainable price range.
I totally agree with you, some people are going ahead of themselves. This CEO, I have noticed, he’s a very reserved man and unless he doesn’t have anything fundamental to say, he doesn’t say nothing!!!! Let’s give him some credit, wait the 4 weeks he said and then we’ll take solid conclusions from there. Furthermore, I wanted to add that VDRM is a company that hasn’t been given too much promotion or pump like ENZC, etc
Followers
|
614
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
73597
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |